Protalix BioTherapeutics, Inc.
PLX
$1.66
$0.085.06%
AMEX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 54.83% | -44.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 54.83% | -44.49% | |||
| Cost of Revenue | -28.24% | 110.50% | |||
| Gross Profit | 406.36% | -86.51% | |||
| SG&A Expenses | 0.81% | -13.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.60% | 29.51% | |||
| Operating Income | 128.28% | -157.50% | |||
| Income Before Tax | 117.71% | -151.01% | |||
| Income Tax Expenses | 539.82% | -113.75% | |||
| Earnings from Continuing Operations | 104.53% | -155.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 104.53% | -155.73% | |||
| EBIT | 128.28% | -157.50% | |||
| EBITDA | 140.33% | -150.36% | |||
| EPS Basic | 104.45% | -151.03% | |||
| Normalized Basic EPS | 117.43% | -146.70% | |||
| EPS Diluted | 104.24% | -174.21% | |||
| Normalized Diluted EPS | 116.78% | -169.41% | |||
| Average Basic Shares Outstanding | 2.68% | 9.10% | |||
| Average Diluted Shares Outstanding | 6.08% | -26.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||